Addressing Unmet Needs In Melanoma

ASCO 2022 Conference Coverage
A

ASCO 2022 on Anti-PD-1 Antibody: Plus One or Plus Two

By ASCO 2022 Conference Coverage FEATURING Adil Daud
By ASCO 2022 Conference Coverage FEATURING Adil Daud
267 views
August 3, 2022
0 Comments
Login to view comments. Click here to Login
04:49
ASCO 2022 Conference Coverage

ASCO 2022 Long-Term Survival in Advanced Melanoma for Pts Treated Wi…

Feat. P. Rutkowski
05:06
ASCO 2022 Conference Coverage

ASCO 2022 on RELATIVITY-047 Trial: Nivolumab + Relatlimab vs. Nivo i…

Feat. P. Rutkowski
16:53
ASCO 2022 Conference Coverage

ASCO 2022: Real-World Evaluation of the Association Between Baseline…

Feat. Z. Eroglu
09:33
ASCO 2022 Conference Coverage

ASCO 2022 on ImmunoCobiVem Study Interim Analysis: The Efficacy &…

Feat. E. Livingstone
07:54
ASCO 2022 Conference Coverage

ASCO 2022 Phase II SECOMBIT Study on Optimal Treatment Sequencing in…

Feat. P. Ascierto
05:48
ASCO 2022 Conference Coverage

ASCO 2022 on the Role of Metastasectomy in Advanced BRAF+ Melanoma D…

Feat. K. Orlova
09:28
ASCO 2022 Conference Coverage

ASCO 2022 Meta-Analysis of Randomized Phase II-III Trials Evaluating…

Feat. P. Francesco Ferrucci
02:01
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Meta-Analysis of Randomized Phase II-III…

Feat. P. Francesco Ferrucci
06:17
Total Health

ASCO 2022 Melanoma Updates

Feat. G. Doolittle
31:55
Penn Medicine Abramson Cancer Center

Penn Medicine on the Treatment Updates in Melanoma: Head-Spinning Pr…

Feat. L. Schuchter
14:22
ASCO 2022 Conference Coverage

ASCO 2022 Nivo + Rela vs. Nivo in Previously Untreated Metastatic/Un…

Feat. E. Lipson
01:37
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on Anti-PD-1 Antibody: Plus One or Plus …

Feat. A. Daud
10:27
ASCO 2022 Conference Coverage

ASCO 2022 Updates on DREAMseq (Doublet, Randomized Evaluation in Adv…

Feat. M. Atkins